Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 34 | 2,730 | 14% |
| 2020 | 22 | 2,203 | 15% |
| 2021 | 29 | 2,407 | 19% |
| 2022 | 28 | 2,326 | 22% |
| 2023 | 34 | 2,564 | 25% |
| 2024 | 37 | 2,575 | 28% |
| 2025 from claims | – | 2,453 2,251–2,595 | 29% |
| 2026 forecast | – | 2,528 2,225–2,918 | 29% |
| 2027 forecast | – | 2,560 2,188–3,050 | 29% |
| 2028 forecast | – | 2,591 2,162–3,173 | 30% |
| 2029 forecast | – | 2,623 2,142–3,289 | 31% |
| 2030 forecast | – | 2,655 2,127–3,402 | 31% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 59% of the cases CMS names in Maryland; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 84% hospital outpatient, 6% surgery center, 10% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 83 | 6,350−1.1%/yr | −1.1%/yr | 3.1 | 27% | 7,730 in 2030+3.3%/yr |
| Texas | 48 | 4,624−1.2%/yr | −1.2%/yr | 2.4 | 16% | 5,220 in 2030+2.1%/yr |
| North Carolina | 30 | 2,572−2.1%/yr | −2.1%/yr | 2.9 | 10% | 2,740 in 2030+1.1%/yr |
| Virginia | 31 | 2,534−2.5%/yr | −2.5%/yr | 2.6 | 15% | 2,790 in 2030+1.6%/yr |
| Georgia | 18 | 2,052−1%/yr | −1%/yr | 2.6 | 8% | 2,340 in 2030+2.2%/yr |
| Tennessee | 25 | 1,879−1.2%/yr | −1.2%/yr | 2.9 | 11% | 1,860 in 2030−0.2%/yr |
| South Carolina | 15 | 1,394−1.5%/yr | −1.5%/yr | 2.2 | 7% | 1,670 in 2030+3.1%/yr |
| Kentucky | 13 | 1,108−5.7%/yr | −5.7%/yr | 2.7 | 9% | 950 in 2030−2.6%/yr |
| Oklahoma | 7 | 1,055−0.1%/yr | −0.1%/yr | 2.3 | 0% | 1,240 in 2030+2.7%/yr |
| Alabama | 8 | 942−6.1%/yr | −6.1%/yr | 2.4 | 13% | 900 in 2030−0.8%/yr |
| Arkansas | 6 | 815−2%/yr | −2%/yr | 2.3 | 14% | 780 in 2030−0.7%/yr |
| Louisiana | 4 | 800−6.4%/yr | −6.4%/yr | 2.2 | 14% | 710 in 2030−2%/yr |
| West Virginia | 4 | 616−2.8%/yr | −2.8%/yr | 3.2 | 5% | 580 in 2030−1.1%/yr |
| Mississippi | 8 | 600−6.8%/yr | −6.8%/yr | 1.7 | 9% | 590 in 2030−0.3%/yr |
| Delaware | 8 | 418−3.4%/yr | −3.4%/yr | 2.6 | 13% | 530 in 2030+4.1%/yr |
| District of Columbia | 4 | 307+6.1%/yr | +6.1%/yr | 5.2 | 31% | 460 in 2030+6.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 65 | 4,904−8.2%/yr | −8.2%/yr | 5.51.1× | 82% | 4,770 in 2030−0.5%/yr |
| Kidney stone management | 91 | 3,844−0.6%/yr | −0.6%/yr | 4.40.9× | 68% | 4,210 in 2030+1.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 35 | 1,684+0.8%/yr | +0.8%/yr | 1.90.7× | 34% | 1,910 in 2030+2.1%/yr |
| Prostatectomy & nephrectomy | 15 | 867−3.9%/yr | −3.9%/yr | 1.00.8× | 0% | 990 in 2030+2.2%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
Acessa Health leads with 56% of company spending on these surgeons in 2025, −22 pts on 2024.
In 2025, 6 companies reported engagement with Maryland’s surgeons worth $127K in consulting, speaking, meals and travel tied to these products, about $3,428 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.